Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
The demand for an effective malaria vaccine is high, with millions of people being affected by the disease every year. A large variety of potential vaccines are under investigation worldwide, and when tested in clinical trials, researchers need to extract as much data as possible from every vaccinated and control volunteer. The use of quantitative real-time polymerase chain reaction (PCR), carried out in real-time during the clinical trials of vaccines designed to act against the liver stage of the parasite's life cycle, provides more information than the gold standard method of microscopy alone and increases both safety and accuracy. PCR can detect malaria parasites in the blood up to 5 days before experienced microscopists see parasites on blood films, with a sensitivity of 20 parasites/mL blood. This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia.
Andrews
Laura
L
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Andersen
Rikke F
RF
Webster
Daniel
D
Dunachie
Susanna
S
Walther
R Michael
RM
Bejon
Philip
P
Hunt-Cooke
Angela
A
Bergson
Gillian
G
Sanderson
Frances
F
Hill
Adrian V S
AV
Gilbert
Sarah C
SC
D000818:Animals; D000852:Anopheles / Q000469:parasitology; D001483:Base Sequence; D002986:Clinical Trials as Topic; D017931:DNA Primers; D006801:Humans; D008288:Malaria / Q000175:diagnosis* / Q000382:microbiology; D017780:Malaria Vaccines; D010961:Plasmodium / Q000235:genetics; D016133:Polymerase Chain Reaction / Q000379:methods*; D012337:RNA, Ribosomal, 18S / Q000235:genetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D017931:DNA Primers; D017780:Malaria Vaccines; D012337:RNA, Ribosomal, 18S